Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Kristian Reich; Richard G. Langley; Mark Lebwohl; Philippe Szapary; Cynthia Guzzo; Newman Yeilding; S. Li; M-C. Hsu; Christopher Em Griffiths

doi:10.1111/j.1365-2133.2011.10257.x

Shared by

Christopher Em Griffiths

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Article 2011 en

Authors

KR
Kristian Reich
RL
Richard G. Langley
ML
Mark Lebwohl

Abstract

1 min read

The totality of available clinical data suggests neither a detrimental nor a beneficial effect of ustekinumab on serious CV events. Additional data are needed to define the net effect of ustekinumab on CV events.

Related publications

Article2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich

Article2016

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

P.C.M. van de Kerkhof, Christopher Em Griffiths, Kristian Reich, Craig L. Leonardi, Andrew Blauvelt, Tsen‐Fang Tsai, Yankun Gong, Jiaqing Huang, C. Papavassilis, Todd Fox

Article2021

Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies

J. Mark FitzGerald, Paul M. O’Byrne, Eric D. Bateman, Peter J Barnes, Jinping Zheng, Stefan Ivanov, Rosa Lamarca, Ulrika Larsdotter, Ulrika Emerath, Gerreke Jansen, Margareta Puu, Vijay K. T. Alagappan, Filip Surmont, Helen K. Reddel

Article2012

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Kristian Reich, Kim Papp, Christopher Em Griffiths, Philippe Szapary, Newman Yeilding, Yasmine Wasfi, Elyssa Ott, Ming Chun Hsu, Mark Lebwohl, Kenneth B. Gordon

Article2022

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Zenas Z N Yiu, G Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Fiona Browne, Ian Evans, Elise Kleyn, Linda Lawson, Kathleen McElhone, Teena Mackenzie, Tess McPherson, Ruth Murphy, Caroline Owen, Eleanor Pearson, Josh Richards, Mark Lunt, A. David Burden, Oras Alabas,

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

Abstract

Discussion(0)

Related publications

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis